Related Experiment Video
Updated: Jul 16, 2025
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
14.7K
Emerging therapies in dyslipidaemias
1IRCCS MultiMedica, Sesto S. Giovanni, Milan, Italy; Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Vascular Pharmacology
|September 16, 2023
Summary
Lowering low-density lipoprotein cholesterol (LDL-C) is crucial for cardiovascular health. New therapies and combination treatments offer enhanced strategies for managing high LDL-C levels and reducing heart disease risk.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Elevated low-density lipoprotein cholesterol (LDL-C) is a significant cause of cardiovascular disease.
- A continuous linear correlation exists between LDL-C reduction and cardiovascular benefit.
- Current guidelines recommend lower LDL-C goals and more effective interventions.
Purpose of the Study:
- To review the current landscape of lipid-lowering therapies.
- To highlight the importance of combination therapies for cardiovascular risk reduction.
- To discuss emerging agents in clinical development.
Main Methods:
- Review of existing literature and clinical guidelines.
- Analysis of current therapeutic options including statins, ezetimibe, and PCSK9 inhibitors.
- Examination of agents in phase 3 clinical trials and under development.
Main Results:
- Lowering LDL-C is a primary strategy for cardiovascular risk reduction.
- Multiple therapeutic classes are available, with new agents progressing through trials.
- Combination therapies show potential for increased treatment effectiveness.
Conclusions:
- Aggressive LDL-C lowering is supported by guidelines.
- A range of pharmacological options are available and expanding.
- Targeting different pathways with combination therapy can optimize cardiovascular risk management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
696
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
696
01:26Atherosclerosis III: Management
12
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
12
01:27Peripheral Artery Disease III: Interprofessional Care
11
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
11
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
210
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
210
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
197
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
197
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
559
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
559